Cancer Cell International (Nov 2023)

Holothurian triterpene glycoside cucumarioside A2-2 induces macrophages activation and polarization in cancer immunotherapy

  • Wen-Han Chuang,
  • Evgeny Pislyagin,
  • Liang-Yu Lin,
  • Ekaterina Menchinskaya,
  • Oleg Chernikov,
  • Valery Kozhemyako,
  • Tatiana Gorpenchenko,
  • Igor Manzhulo,
  • Elena Chaikina,
  • Irina Agafonova,
  • Alexandra Silchenko,
  • Sergey Avilov,
  • Valentin Stonik,
  • Shey-Cherng Tzou,
  • Dmitry Aminin,
  • Yun-Ming Wang

DOI
https://doi.org/10.1186/s12935-023-03141-z
Journal volume & issue
Vol. 23, no. 1
pp. 1 – 17

Abstract

Read online

Abstract Background Despite intensive developments of adoptive T cell and NK cell therapies, the efficacy against solid tumors remains elusive. Our study demonstrates that macrophage-based cell therapy could be a potent therapeutic option against solid tumors. Methods To this end, we determine the effect of a natural triterpene glycoside, cucumarioside A2-2 (CA2-2), on the polarization of mouse macrophages into the M1 phenotype, and explore the antitumor activity of the polarized macrophage. The polarization of CA2-2-pretreated macrophages was analyzed by flow cytometry and confocal imaging. The anti-cancer activity of CA2-2 macrophages was evaluated against 4T1 breast cancer cells and EAC cells in vitro and syngeneic mouse model in vivo. Results Incubation of murine macrophages with CA2-2 led to polarization into the M1 phenotype, and the CA2-2-pretreated macrophages could selectively target and kill various types of cancer in vitro. Notably, loading near-infrared (NIR) fluorochrome-labeled nanoparticles, MnMEIO-mPEG-CyTE777, into macrophages substantiated that M1 macrophages can target and penetrate tumor tissues in vivo efficiently. Conclusion In this study, CA2-2-polarized M1 macrophages significantly attenuated tumor growth and prolonged mice survival in the syngeneic mouse models. Therefore, ex vivo CA2-2 activation of mouse macrophages can serve as a useful model for subsequent antitumor cellular immunotherapy developments.

Keywords